Inari Medical soars on Stryker acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BTIG Downgrades Inari Medical Inc. (NARI) to Neutral
January 7, 2025 4:09 PM ESTBTIG analyst Marie Thibault downgraded Inari Medical Inc. (NASDAQ: NARI) from Buy to Neutral.
The analyst comments "We are downgrading NARI shares to Neutral following the announcement on Monday, January 6 that Stryker (SYK, Buy, $394 PT; Analyst: Zimmerman) entered a definitive agreement to... More
Jefferies Downgrades Inari Medical Inc. (NARI) to Hold
January 7, 2025 11:49 AM ESTJefferies analyst Matthew Taylor downgraded Inari Medical Inc. (NASDAQ: NARI) from Buy to Hold with a price target of $80.00 (from $70.00).
The analyst comments "After the market close, SYK announced an agreement to acquire NARI for $80/shr in cash, equating to a fully... More
BofA Securities Reiterates Buy Rating on Stryker (SYK)
January 7, 2025 8:07 AM ESTBofA Securities analyst Travis Steed reiterated a Buy rating and $450.00 price target on Stryker (NYSE: SYK)
The analyst comments "Inside we include our pro forma deal model. We estimate the EPS dilution in year 1 is only slightly dilutive (around 1-3% dilutive) and... More
